Nektar Therapeutics (NKTR) Exchange Rate Effect (2010 - 2025)
Nektar Therapeutics (NKTR) posted quarterly Exchange Rate Effect of $1000.0 for Q3 2025, up 103.57% year-over-year from $491.23 in Q3 2024, and down 83.33% quarter-over-quarter from $6000.0 in Q2 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Exchange Rate Effect (2010 - 2025) Analysis & Trends
Nektar Therapeutics' Exchange Rate Effect history runs 16 years deep, the most recent figure standing at $1000.0 for Q3 2025.
- In Q3 2025, Exchange Rate Effect rose 103.57% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $7000.0 (up 133.33% YoY), while the FY2025 annual figure was $6000.0, up 250.0% from the prior year.
- Exchange Rate Effect for Q3 2025 stood at $1000.0, down from $6000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $107000.0 in Q2 2023, with the low at -$295000.0 in Q3 2022.
- The 5-year median for Exchange Rate Effect is -$8000.0 (2024), against an average of -$18684.2.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect tumbled 1080.0% in 2022, then soared 700.0% in 2025.
- Nektar Therapeutics' Exchange Rate Effect stood at -$10000.0 in 2021, then jumped by 650.0% to $55000.0 in 2022, then slumped by 85.45% to $8000.0 in 2023, then soared by 312.5% to $33000.0 in 2024, then sank by 96.97% to $1000.0 in 2025.
- Business Quant data shows NKTR's Exchange Rate Effect at $1000.0 in Q3 2025, $6000.0 in Q2 2025, and -$1000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | 33,000.00 |
| Sep 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | -98,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 55,000.00 |
| Sep 30, 2022 | -295,000.00 |
| Jun 30, 2022 | -70,000.00 |
| Mar 31, 2022 | -17,000.00 |
| Dec 31, 2021 | -10,000.00 |
| Sep 30, 2021 | -25,000.00 |
| Jun 30, 2021 | -37,000.00 |
| Mar 31, 2021 | -20,000.00 |
| Dec 31, 2020 | 11,000.00 |